Autophagy Signaling: ULK1 Initiation, LC3 Lipidation, Cargo Receptors, and Mitophagy via PINK1/Parkin

# Autophagy Signaling: ULK1 Initiation, LC3 Lipidation, Cargo Receptors, and Mitophagy via PINK1/Parkin

For Research Use Only. Not for human or animal therapeutic use.

---

Introduction: Cellular Self-Digestion as a Survival Mechanism

Autophagy (from Greek: auto = self, phagy = eating) is a fundamental catabolic process by which eukaryotic cells deliver cytoplasmic cargo — damaged organelles, protein aggregates, invading pathogens, and surplus macromolecules — to the lysosome for degradation and nutrient recycling. Far from being a simple garbage disposal, autophagy is a highly regulated, selective quality-control system that integrates nutrient sensing, organelle homeostasis, immune defense, and cell death decisions.

Three morphologically distinct autophagy pathways exist: macroautophagy (formation of a double-membrane autophagosome that engulfs cargo and fuses with lysosomes), microautophagy (direct lysosomal membrane invagination engulfing cytoplasmic material), and chaperone-mediated autophagy (CMA) (KFERQ-motif proteins translocated directly into lysosomes via LAMP-2A/Hsp70). This article focuses on macroautophagy (hereafter "autophagy"), which is best characterized mechanistically and has the most research tools available.

Autophagy was identified in yeast through genetic screens by Yoshinori Ohsumi (2016 Nobel Prize in Physiology or Medicine), who characterized ATG (AuTophaGy) genes. Mammalian autophagy is regulated by a conserved hierarchy of protein complexes: the ULK1 kinase complex initiates the process; the Beclin-1/VPS34 PI3K complex nucleates the phagophore; ATG proteins elongate the isolation membrane; LC3/GABARAP family members mark the mature autophagosome; and cargo receptors (p62/SQSTM1, NBR1, NDP52, OPTN) provide selectivity. The process is negatively regulated by mTORC1 during nutrient sufficiency and positively activated by AMPK during energy stress.

---

Upstream Regulation: mTORC1, AMPK, and the Nutrient Sensing Interface

mTORC1: The Master Autophagy Suppressor

Under nutrient-replete conditions, mTORC1 (mechanistic target of rapamycin complex 1) phosphorylates and inhibits the ULK1 initiation complex at multiple sites, suppressing autophagy induction. Key mTORC1 phosphorylation events:

• •ULK1 S757 (human; S758 in some isoforms): Direct mTORC1 substrate site; phosphorylation disrupts ULK1 interaction with AMPK, preventing AMPK-mediated ULK1 activation
• •ATG13 S258: Disrupts ATG13 interaction with ULK1 and FIP200
• •ATG14 S29: Reduces ATG14-containing VPS34 complex activity

mTORC1 activity is itself regulated by nutrient sensing through the Rag GTPase system at the lysosomal surface (amino acid sensing), the FLCN/FNIP1 complex, and growth factor inputs through PI3K/AKT/TSC1/2. Rapamycin (and its analogs rapalogs) allosterically inhibit mTORC1 by forming rapamycin·FKBP12 complex that docks on the FRB domain of mTOR, partially inhibiting substrate phosphorylation. Torin1 and Torin2 (ATP-competitive mTOR kinase inhibitors) more completely inhibit both mTORC1 and mTORC2 and are stronger autophagy inducers than rapamycin, particularly for ULK1 S757 dephosphorylation.

mTOR inhibitors as autophagy research tools:

AMPK: The Energy Sensor That Activates Autophagy

AMP-activated protein kinase (AMPK) is activated when cellular AMP:ATP ratio rises (energy stress, glucose deprivation, hypoxia). Active AMPK directly promotes autophagy by two complementary mechanisms:

1. Direct ULK1 phosphorylation: AMPK phosphorylates ULK1 at S317, S555, S574, S637 (human; multiple sites), activating the kinase complex and triggering autophagy initiation

2. mTORC1 inhibition: AMPK phosphorylates TSC2 (activating the TSC1/2 GAP toward Rheb) and directly phosphorylates Raptor at S792, together suppressing mTORC1 activity

AICAR (AICA-riboside, 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside) is phosphorylated intracellularly to ZMP, an AMP mimetic that activates AMPK; used experimentally to induce AMPK-mediated autophagy. Compound C (dorsomorphin) is an ATP-competitive AMPK inhibitor (IC50 ~109 nM for AMPKα1/2) used to confirm AMPK-dependent autophagy responses, though it has off-target effects on BMP receptors and other kinases.

TFEB: Lysosomal Biogenesis and Autophagy Gene Transcription

Transcription factor EB (TFEB) is a master regulator of lysosomal biogenesis and autophagy gene transcription. TFEB contains a CLEAR (Coordinated Lysosomal Expression and Regulation) motif recognition domain; its ~500 target genes include LAMP1, LAMP2, CTSD (cathepsin D), LC3B/MAP1LC3B, BECN1, MCOLN1 (mucolipin-1/TRPML1). mTORC1 phosphorylates TFEB at S211, creating a 14-3-3 binding site that retains TFEB in the cytoplasm. When mTORC1 is inhibited (starvation, Torin1), TFEB S211 is dephosphorylated by calcineurin, TFEB translocates to the nucleus, and autophagy/lysosomal genes are transcriptionally upregulated — a feedforward amplification of the autophagy response.

---

The ULK1 Initiation Complex

Complex Composition and Architecture

The ULK1 (Unc-51-like autophagy activating kinase 1) complex is the most upstream autophagy-specific effector, comprising:

• •ULK1 (or its paralog ULK2): Serine/threonine kinase; ~112 kDa; contains N-terminal kinase domain, proline/serine-rich region, and C-terminal EAT/MIT domain for ATG13 and FIP200 interaction
• •ATG13: Scaffold; bridges ULK1 to FIP200; contains HORMA domain; regulated by mTORC1 phosphorylation
• •FIP200 (RB1CC1): Large scaffold (~200 kDa); coiled-coil domain; essential for autophagosome initiation; the functional ortholog of yeast Atg17
• •ATG101: Stabilizes ATG13 and prevents its degradation; required for full complex activity; contains HORMA domain that interacts with ATG13 HORMA

ULK1 Activation and Substrates

Upon mTORC1 inhibition (dephosphorylation of ULK1 S757 and ATG13 S258) and AMPK activation (phosphorylation of ULK1 S317/S555), ULK1 undergoes autophosphorylation (S1047) and becomes active. Active ULK1 phosphorylates:

• •Beclin-1 S14/S30: Activates the Beclin-1/VPS34 PI3K nucleation complex
• •ATG14 S29: Activates the autophagy-specific VPS34 complex (Complex I)
• •AMBRA1 S52: Releases AMBRA1 from dynein motor complex, allowing AMBRA1 to activate TRAF6/ubiquitin-mediated PI3K complex activation
• •FUNDC1 S17: Activates the mitophagy receptor FUNDC1 in hypoxic conditions
• •RAB7A S72: Regulates late endosomal trafficking; promotes autophagosome-lysosome fusion

SBI-0206965: A selective ULK1/ULK2 inhibitor (ATP-competitive, IC50 ~108 nM for ULK1); blocks ULK1-mediated autophagy induction; used to confirm ULK1-dependent autophagy without affecting mTORC1. MRT68921 is an alternative dual ULK1/2 inhibitor.

---

The Beclin-1/VPS34 Nucleation Complex

VPS34 Class III PI3K and Its Complexes

VPS34 (Vacuolar Protein Sorting 34, encoded by PIK3C3) is the sole class III phosphatidylinositol 3-kinase in mammals, generating phosphatidylinositol 3-phosphate (PI3P) from PI. PI3P on nascent phagophore membranes serves as a docking platform for FYVE- and PX-domain-containing effector proteins (DFCP1, WIPI1/2, WIPI3/4) that drive membrane expansion.

VPS34 functions in at least two distinct complexes:

• •Complex I (autophagy): VPS34 + VPS15 (p150) + Beclin-1 + ATG14L (Barkor) ± AMBRA1; localized to the ER/ER-mitochondria contact sites; generates PI3P for phagophore formation
• •Complex II (endosomal): VPS34 + VPS15 + Beclin-1 + UVRAG ± Rubicon; localized to late endosomes/lysosomes; regulates endocytic trafficking and autophagosome-lysosome fusion

Beclin-1: Autophagy Platform and BCL-2 Regulation

Beclin-1 (BECN1) is the mammalian ortholog of yeast Atg6; it functions as the central scaffold of the VPS34 complexes. Beclin-1 contains:

• •BH3 domain: Interacts with anti-apoptotic BCL-2 family members (BCL-2, BCL-XL, MCL-1) — this interaction sequesters Beclin-1 in the cytoplasm and inhibits autophagy; BH3 mimetics (ABT-737, ABT-199/venetoclax) disrupt BCL-2/Beclin-1 interaction, releasing Beclin-1 to activate autophagy
• •CCD (coiled-coil domain): Mediates interaction with ATG14L and UVRAG
• •BARAD (β-α repeated, autophagy-specific domain): Activates VPS34 lipid kinase activity

Beclin-1 phosphorylation by ULK1 (S14/S30): Activates the autophagy-specific Complex I; this creates positive feedback between ULK1 activation and PI3P generation.

Spautin-1: Inhibitor of USP10 and USP13 deubiquitinases that stabilize VPS34; promotes Beclin-1 ubiquitination and degradation; used as an autophagy inhibitor.

3-Methyladenine (3-MA): Classic pan-PI3K inhibitor; at low concentrations inhibits class III PI3K (VPS34) selectively; at high concentrations/prolonged treatment inhibits class I PI3K and can paradoxically induce autophagy; widely used at 5–10 mM to inhibit autophagy initiation in research.

Wortmannin: Irreversible pan-PI3K inhibitor (covalent binding to catalytic cysteine); also inhibits VPS34; used at 100–200 nM to block autophagy; caveat: also inhibits class I PI3K/AKT.

---

Phagophore Elongation: ATG Conjugation Systems

ATG12–ATG5–ATG16L1 Complex

Two ubiquitin-like conjugation systems operate sequentially to produce lipidated LC3 on the autophagosome membrane:

Conjugation system 1:

1. ATG12 is activated by ATG7 (E1-like activating enzyme) in an ATP-dependent thioester bond

2. ATG12 is transferred to ATG10 (E2-like conjugating enzyme)

3. ATG12 is conjugated to ATG5 (isopeptide bond to K130 on ATG5)

4. ATG12–ATG5 dimer associates non-covalently with ATG16L1 (the WD-repeat E3-like domain that specifies membrane targeting)

5. The ATG12–ATG5–ATG16L1 complex (~800 kDa oligomer via ATG16L1 coiled-coil) is recruited to the phagophore outer membrane by FIP200 and WIPI2 interactions

LC3/GABARAP Lipidation

Conjugation system 2 (LC3 lipidation):

1. Pro-LC3 is cleaved by ATG4B protease at C-terminal glycine to yield LC3-I (cytoplasmic, soluble)

2. LC3-I is activated by ATG7 (shared E1 with conjugation system 1)

3. LC3-I is transferred to ATG3 (E2-like)

4. The ATG12–ATG5–ATG16L1 complex (acting as E3-like) catalyzes transfer of LC3 to phosphatidylethanolamine (PE) on the phagophore membrane, producing LC3-II (membrane-anchored, lipidated)

5. LC3-II on the outer autophagosome membrane is cleaved by ATG4B after fusion with lysosomes; LC3-II on the inner membrane is degraded within the autolysosome

LC3 family members: LC3A (MAP1LC3A), LC3B (MAP1LC3B, most widely studied), LC3C (MAP1LC3C); GABARAP, GABARAPL1, GABARAPL2 (GATE-16). LC3B is the standard autophagy marker; GABARAP subfamily may be preferentially involved in late autophagosome closure and fusion.

LC3-I vs LC3-II by Western blot: LC3-I (~16 kDa) and LC3-II (~14 kDa, faster migration due to PE modification); LC3-II/LC3-I ratio increases with autophagy induction; must measure in the presence of lysosomal inhibitors to assess flux (see Protocol 1).

---

Selective Autophagy Cargo Receptors

p62/SQSTM1: The Archetype Cargo Receptor

p62 (Sequestosome-1, SQSTM1) is the best-characterized selective autophagy receptor. It contains:

• •PB1 domain (N-terminal): Self-polymerization domain; forms filamentous oligomers that cluster ubiquitinated cargo
• •ZZ domain: Binds N-degron pathway substrates
• •TRAF6-binding domain (TB): Interacts with TRAF6 for NF-κB signaling
• •LIR motif (LC3-Interacting Region, W338-x-x-L341): Binds LC3/GABARAP family members directly; LIR motif (WXXL/YXXL/FXXL) is essential for cargo delivery to autophagosomes
• •UBA domain (C-terminal): Binds K48- and K63-linked ubiquitin chains on cargo

When ubiquitinated cargo accumulates (damaged mitochondria, protein aggregates, bacteria), p62 oligomers cluster the cargo via its UBA domain and tether the cluster to the autophagosome via LIR–LC3B interaction. p62 itself is degraded in the autolysosome; p62 accumulation (Western blot or IF puncta) indicates impaired autophagy flux or enhanced autophagic substrate delivery.

p62 as an NRF2 activator: p62 also binds KEAP1 (via its KEAP1-interacting region, KIR: DSTGE motif), competing with NRF2 for KEAP1 binding; accumulated p62 releases NRF2 from KEAP1-mediated ubiquitination, driving antioxidant gene expression. This p62-KEAP1-NRF2 axis connects autophagy status to oxidative stress response.

Additional Selective Cargo Receptors

---

Mitophagy: The PINK1/Parkin Axis

PINK1 Kinase: The Mitochondrial Damage Sensor

PTEN-induced kinase 1 (PINK1, PINK1) is a serine/threonine kinase with a mitochondrial targeting sequence (MTS) and a kinase domain. In healthy mitochondria with intact membrane potential (ΔΨm), PINK1 is imported into the inner mitochondrial membrane (IMM) via TOM/TIM complex, cleaved by PARL (presenilin-associated rhomboid-like protease) and MPP (mitochondrial processing peptidase), and retrotranslocated to the cytoplasm where it is rapidly degraded by the proteasome — keeping steady-state PINK1 levels low.

Upon mitochondrial damage (membrane potential collapse by CCCP, uncouplers, mtDNA stress, or oxidative damage), import and PARL cleavage are blocked. PINK1 accumulates on the outer mitochondrial membrane (OMM), where it dimerizes and transautophosphorylates its activation loop (S228/S402). Stabilized PINK1 then phosphorylates two key substrates:

1. Ubiquitin at S65: PINK1 phosphorylates ubiquitin on Ser65, generating pS65-Ub on proteins already ubiquitinated on the mitochondrial surface (by constitutively active E3s like MARCH5/MUL1)

2. Parkin UBL domain at S65: Identical phosphorylation event activates Parkin

Parkin: E3 Ubiquitin Ligase Amplification

Parkin (PRKN) is a cytoplasmic RING-between-RING (RBR) E3 ubiquitin ligase that is recruited to depolarized mitochondria in a PINK1-dependent manner. In its basal state, Parkin is autoinhibited: the N-terminal UBL (ubiquitin-like) domain occupies and blocks the RING1 and RING2 domains (determined by crystal structure).

Activation cascade:

1. PINK1 phosphorylates pS65-Ub on the mitochondrial surface

2. pS65-Ub recruits cytoplasmic Parkin (pS65-Ub binds a hydrophobic patch on Parkin with Kd ~1–5 µM)

3. PINK1 phosphorylates Parkin UBL S65, releasing autoinhibition

4. Activated Parkin (doubly activated by pS65-Ub binding + S65 phosphorylation) massively ubiquitinates OMM proteins: TOMM20, TOMM40, VDAC1/2/3, MFN1/MFN2 (mitofusins), RHOT1/2 (Miro1/2), FIS1

5. K11/K48/K63-linked polyubiquitin chains on OMM proteins recruit proteasomal degradation machinery (for early Miro/Mfn degradation) and autophagy cargo receptors (NDP52, OPTN, TAX1BP1 primarily; p62 secondary)

6. Cargo receptors bridge ubiquitinated OMM to LC3 on the growing autophagosome membrane

Positive feedback: pS65-Ub generated by PINK1 + Parkin-generated Ub chains on OMM create a self-amplifying pS65-Ub signal that recruits more Parkin and drives complete mitochondrial ubiquitination within ~30–60 min of membrane potential collapse.

Mitophagy Research Tools

• •CCCP (carbonyl cyanide m-chlorophenyl hydrazone): Proton uncoupler; collapses ΔΨm irreversibly; strongly activates PINK1/Parkin mitophagy; use 10–20 µM for 2–24 h
• •Oligomycin + antimycin A (OA): Inhibits ATP synthase + complex III; collapses ΔΨm without proton leak artifact; preferred for quantitative mitophagy studies; 1 µM each
• •Valinomycin: K⁺ ionophore; collapses ΔΨm in K⁺-rich environments; activates PINK1 stabilization
• •MitoSOX Red: Mitochondrial superoxide indicator; distinguishes ROS-driven mitophagy from depolarization-driven
• •mt-Keima: Mitochondria-targeted Keima protein (ratiometric pH-sensitive fluorescent protein); green at neutral pH (healthy mito), red at acidic pH (lysosomal); irreversible color change upon autophagosome-lysosome fusion; gold standard for mitophagy quantification
• •pS65-Ub antibody (Cell Signaling #62802): Detects PINK1-phosphorylated ubiquitin; Western and IF readout of PINK1 activity
• •Parkin-S65A knock-in: Cannot be activated by PINK1; genetic control for Parkin-dependent mitophagy

---

Autophagosome-Lysosome Fusion and Autolysosome Function

SNARE-Mediated Fusion

Autophagosome-lysosome fusion requires:

• •STX17 (syntaxin-17): Autophagosome-localized SNARE; recruited to closed autophagosomes (not phagophores); pairs with SNAP29 on the autophagosome membrane
• •VAMP7/VAMP8: Lysosomal R-SNAREs; complete the SNARE complex with STX17/SNAP29
• •HOPS complex: Tethering complex (VPS11/16/18/33/39/41) that bridges autophagosomes and lysosomes via RAB7 interaction; required before SNARE assembly

RAB7 (the late endosomal/lysosomal Rab GTPase) is essential for both autophagosome-lysosome fusion and endosome maturation. RAB7 is active (GTP-bound) on mature lysosomes and is required for HOPS complex recruitment. Dominant-negative RAB7-T22N blocks lysosomal fusion and causes autophagosome accumulation.

Lysosomal Acidification and Hydrolase Function

Autolysosomes must maintain pH <5.0 for efficient hydrolase function. The vacuolar H⁺-ATPase (V-ATPase) on the lysosomal membrane pumps protons into the lumen. V-ATPase also acts as an amino acid sensor that activates mTORC1 via the Ragulator complex — coupling lysosomal digestive function to mTORC1 reactivation after autophagy.

Lysosomal inhibitors used in autophagy flux research:

• •Chloroquine (CQ): Weak base; accumulates in lysosomes; raises lysosomal pH → inhibits acidification → blocks hydrolase activity → blocks autophagosome-lysosome fusion and autophagic substrate degradation; causes LC3-II and p62 accumulation; standard late-stage autophagy inhibitor; use 10–50 µM
• •Hydroxychloroquine (HCQ): Chloroquine analog; same mechanism
• •Bafilomycin A1 (Baf A1): Selective V-ATPase inhibitor; blocks lysosomal acidification; also inhibits autophagosome-lysosome fusion at pre-fusion step; most commonly used lysosomal inhibitor in autophagy research; use 50–200 nM (lower concentrations than CQ but more selective); Baf A1 effectively blocks autophagic flux and causes LC3-II/p62 accumulation
• •Leupeptin: Cysteine and serine protease inhibitor; blocks lysosomal cathepsins (B, L, H); reduces but does not eliminate autophagic substrate degradation; use 200 µM
• •E64d + pepstatin A combination: Membrane-permeable broad-spectrum lysosomal protease inhibitor cocktail; blocks cathepsins B/L (E64d) and D (pepstatin A); used at 10 µg/mL each to block autophagy flux at the degradation step

---

Research Tools Table

---

Experimental Protocols for Research Applications

Protocol 1: LC3-II Flux Assay — Gold Standard Autophagy Measurement

Objective: Distinguish autophagy induction from lysosomal blockade by measuring LC3-II turnover; the definitive autophagy flux assay.

Materials: Rapamycin or Torin1 (autophagy inducer), Bafilomycin A1 (Baf A1, lysosomal inhibitor), anti-LC3B antibody (Cell Signaling #3868 or Abcam #ab192890), anti-p62/SQSTM1 (Cell Signaling #8025), anti-β-actin or anti-GAPDH (loading control).

Procedure:

1. Plate cells; allow 24 h recovery; serum-free starvation for 2 h to provide a baseline autophagy condition

2. Set up 6 conditions (in parallel wells):

- Vehicle (DMSO control)

- Rapamycin (100 nM, 4 h) — autophagy inducer

- Torin1 (250 nM, 4 h) — strong autophagy inducer

- Baf A1 (100 nM, 4 h) — lysosomal inhibitor alone

- Rapamycin + Baf A1 (4 h co-treatment) — inducer + flux block

- Torin1 + Baf A1 (4 h co-treatment)

3. Lyse in RIPA + protease inhibitors; SDS-PAGE (12–15% gel to resolve LC3-I at ~16 kDa and LC3-II at ~14 kDa); Western blot LC3B, then p62, then loading control

4. Interpretation of flux:

- True autophagy induction: LC3-II increases with inducer alone AND further increases with Baf A1 addition (LC3-II flux = [LC3-II + Baf A1] − [LC3-II alone])

- Lysosomal blockade only: LC3-II increases with Baf A1 but NOT further with inducer + Baf A1

- p62 decreases with inducer alone (flux) or accumulates with Baf A1 (blockade)

Expected result: Rapamycin: moderate LC3-II increase; Torin1: strong LC3-II increase; Baf A1 alone: LC3-II accumulates (blockade of degradation); Rapamycin/Torin1 + Baf A1: higher LC3-II than either alone (confirming increased flux). p62 decreases with effective autophagy induction; accumulates with Baf A1.

---

Protocol 2: GFP-LC3 Puncta Quantification by Fluorescence Microscopy

Objective: Visualize autophagosome formation as GFP-LC3 fluorescent puncta; quantify autophagy at single-cell resolution.

Materials: GFP-LC3 stable or transiently transfected cell line, Rapamycin/Torin1 (inducers), Baf A1 (CQ as alternative), confocal or widefield fluorescence microscope, ImageJ/CellProfiler for puncta counting.

Procedure:

1. Transfect cells with GFP-LC3 plasmid (e.g., from Addgene: pEGFP-LC3 #24920); allow 24 h expression; seed on glass coverslips or optical-bottom plates

2. Treat: vehicle / Rapamycin 100 nM 4 h / Torin1 250 nM 4 h / Baf A1 100 nM 4 h / starved (HBSS, 2 h) / starved + Baf A1

3. Fix with 4% PFA, 15 min; DAPI stain

4. Image: 60× or 63× oil objective; GFP channel; take ≥ 5 fields per condition; ~50–100 cells per condition

5. CellProfiler pipeline: identify cells (DAPI), identify GFP-LC3 puncta within cells (minimum 3-pixel diameter, intensity threshold 2× background), count puncta per cell

6. Critical controls: GFP alone (no puncta); GFP-LC3-G120A (lipidation mutant, no puncta) — confirm puncta represent membrane-bound LC3-II

Expected result: Vehicle: 2–5 diffuse puncta/cell; Rapamycin: 10–20 puncta/cell; Torin1: 15–30 puncta/cell; HBSS starvation: 15–25 puncta/cell; Baf A1: 20–40 puncta/cell (blocked degradation); Torin1 + Baf A1: highest puncta count. 3-MA pre-treatment (5 mM, 1 h) blocks Torin1-induced puncta.

---

Protocol 3: Mitophagy Quantification via mt-Keima Flow Cytometry

Objective: Quantify mitophagy at the population level using pH-ratiometric mt-Keima reporter.

Materials: mt-Keima stable cell line (lentiviral; available from Addgene #56018); CCCP (10 µM) or Oligomycin/Antimycin A (1 µM each); Baf A1 (100 nM, mitophagy inhibitor control); flow cytometer with 405 nm (green/neutral) and 561 nm (red/acidic) laser excitation; 620 nm emission detection for both.

Procedure:

1. Treat mt-Keima cells: vehicle / CCCP 10 µM 24 h / OA (1 µM each) 24 h / CCCP + Baf A1 (lysosomal block control)

2. Trypsinize; wash in PBS; resuspend in 200 µL PBS; keep on ice

3. Acquire on flow cytometer: excite at 405 nm (neutral/green, mitochondria in cytoplasm) and 561 nm (acidic/red, mitochondria in lysosome); collect emission at 620 nm for both

4. Calculate mitophagy index: 561 nm excitation / 405 nm excitation ratio per cell; cells with high ratio (red-shifted) have high mitophagy; gate mitophagy-high population (>2-fold ratio over vehicle)

5. Express as % mitophagy-high cells; CCCP + Baf A1 blocks red shift (confirms lysosomal delivery)

Expected result: Vehicle: ~2–5% cells in mitophagy-high gate; CCCP 24 h: 15–40% mitophagy-high; OA 24 h: 10–25% mitophagy-high; CCCP + Baf A1: maintains or reduces mitophagy-high gate (Baf A1 prevents lysosomal acidification → Keima stays green even after delivery → reduced apparent mitophagy index, confirming lysosomal origin of the red signal).

---

Protocol 4: PINK1/Parkin Mitophagy Pathway Western Analysis

Objective: Document PINK1 stabilization, Parkin recruitment/S65 phosphorylation, and OMM substrate ubiquitination during mitophagy induction.

Materials: CCCP or OA, anti-PINK1 (Novus NBP2-36488), anti-Parkin (Cell Signaling #4211), anti-pS65-Ub (Cell Signaling #62802), anti-Mfn1 (Abcam ab57602), anti-Mfn2 (Abcam ab56889), anti-VDAC1 (Abcam ab14734), mitochondrial fraction isolation kit.

Procedure:

1. Treat WT and PINK1-KO or Parkin-KO cells (as genetic controls) with CCCP (10–20 µM) for 0, 1, 2, 4, 8 h

2. Prepare: (A) whole cell lysate; (B) mitochondria-enriched fraction (differential centrifugation: 600 × g 10 min remove debris → 10,000 × g 10 min pellet mitochondria)

3. Whole cell lysate: PINK1 (stabilizes at OMM, detectable only with depolarization); pS65-Ub (increases); p62 (recruited to mitochondria)

4. Mitochondrial fraction: Parkin (recruited from cytoplasm); pS65-Ub (concentrated); Mfn1/Mfn2/VDAC1 (decrease as they are ubiquitinated and proteasomally degraded or consumed by mitophagy)

5. Cytoplasmic fraction: Parkin (decreases with recruitment); PINK1 cleaved form (in healthy mito)

Expected result: CCCP 1–2 h: PINK1 stabilized at OMM (whole cell); pS65-Ub accumulates; Parkin shifts from cytoplasm to mitochondria. CCCP 4–8 h: Mfn1/Mfn2 decrease (proteasomal degradation); VDAC1 decrease (mitophagy). PINK1-KO: no PINK1, no pS65-Ub, no Parkin recruitment. Parkin-KO: PINK1 stabilized (pS65-Ub present) but no Parkin, reduced Mfn1/VDAC1 loss.

---

Protocol 5: Tandem mCherry-GFP-LC3 Flux Reporter

Objective: Distinguish autophagosomes from autolysosomes in live or fixed cells using differential pH sensitivity of tandem fluorescent LC3.

Materials: mCherry-GFP-LC3 plasmid (Addgene #22418; Kimura 2007); stable or transient expression; Torin1 or starvation; Baf A1 or CQ; confocal or widefield fluorescence microscope.

Principle: GFP fluorescence is quenched at lysosomal pH (<5.5); mCherry is pH-stable to pH 4. Therefore:

• •Autophagosome (pre-fusion): GFP+ / mCherry+ = yellow/orange puncta
• •Autolysosome (post-fusion): GFP− / mCherry+ = red-only puncta (GFP quenched by lysosomal acid)
• •Lysosomal blockade (Baf A1): Both GFP+ / mCherry+ remain (fusion blocked or acidification blocked) = yellow puncta accumulate without red conversion

Procedure:

1. Express mCherry-GFP-LC3; treat: vehicle / Torin1 250 nM 4 h / HBSS starvation 2 h / Baf A1 100 nM 4 h / Torin1 + Baf A1

2. Live-cell imaging or fix with 4% PFA (for fixed: no permeabilization needed, only surface epitopes)

3. Image GFP (488 nm excitation) and mCherry (561 nm excitation) channels simultaneously; confocal preferred

4. Quantify per cell: (A) total puncta (GFP + mCherry merged), (B) yellow puncta (autophagosomes), (C) red-only puncta (autolysosomes); flux ratio = red-only / total puncta

Expected result: Vehicle: ~3–8 puncta/cell, mix of yellow and red; Torin1: increase in both yellow and red puncta (healthy flux); HBSS: similar to Torin1; Baf A1: all puncta remain yellow (no acidification → no GFP quenching); Torin1 + Baf A1: many yellow puncta, few red (confirms autophagy induction with flux blocked). Presence of red-only puncta confirms autophagic flux to acidic compartment.

---

Disease Contexts

Neurodegeneration: Parkinson's Disease

PINK1 and Parkin are the most commonly mutated genes in familial Parkinson's disease (PD). Loss-of-function mutations in PINK1 or PRKN impair mitophagy, leading to accumulation of damaged, ROS-producing mitochondria in dopaminergic neurons. iPSC-derived dopaminergic neurons from PINK1/Parkin-mutant patients show impaired mitophagy (measured by mt-Keima), elevated mitochondrial ROS (MitoSOX), and enhanced neurodegeneration. Compounds that activate mitophagy (urolithin A, NAD⁺ precursors via SIRT1/AMPK) are studied in PD research models.

Cancer: Autophagy as Context-Dependent Tumor Suppressor/Promoter

Autophagy has paradoxical roles in cancer: in early tumorigenesis, autophagy suppresses accumulation of damaged organelles and oncogenic reactive oxygen species; in established tumors, autophagy provides stress tolerance and enables survival under nutrient deprivation. KRAS-mutant pancreatic cancers are particularly autophagy-dependent: genetic or pharmacologic autophagy inhibition (chloroquine, hydroxychloroquine) reduces tumor cell survival in KRAS-mutant models and is synergistic with MEK inhibitors in research studies. Beclin-1 (BECN1) is monoallelically deleted in ~50% of breast and ovarian cancers, implicating autophagy deficiency in tumor initiation.

Lysosomal Storage Disorders

Lysosomal storage disorders (LSDs) including Gaucher disease, Niemann-Pick type C, and neuronal ceroid lipofuscinoses all show impaired autophagic flux due to lysosomal dysfunction. In NPC (Niemann-Pick type C, NPC1 gene defect causing cholesterol trafficking block), autophagosomes accumulate as their fusion/degradation is impaired by dysfunctional lysosomes. Research in NPC and other LSDs uses the LC3 flux assay and mCherry-GFP-LC3 reporter to characterize autophagy bottlenecks and screen potential rescue compounds.

Infectious Disease: Xenophagy

Autophagy can directly eliminate intracellular pathogens (xenophagy). Mycobacterium tuberculosis is delivered to autophagosomes via NDP52 and p62 recognizing ubiquitinated bacterial surface proteins, and rapamycin-induced autophagy reduces bacterial burden in macrophage research models. Salmonella and group A Streptococcus are also xenophagy targets. Conversely, some pathogens (Legionella, Brucella) exploit autophagic membranes for replication, making autophagy modulation a complex target in infection research.

---

Literature References

1. Mizushima N, Yoshimori T, Ohsumi Y. The role of Atg proteins in autophagosome formation. Annu Rev Cell Dev Biol. 2011;27:107-132. PMID: 21801009

2. Dikic I, Elazar Z. Mechanism and medical implications of mammalian autophagy. Nat Rev Mol Cell Biol. 2018;19(6):349-364. PMID: 29618831

3. Pickrell AM, Youle RJ. The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease. Neuron. 2015;85(2):257-273. PMID: 25611507

4. Kane LA, Lazarou M, Fogel AI, et al. PINK1 phosphorylates ubiquitin to activate Parkin E3 ubiquitin ligase activity. J Cell Biol. 2014;205(2):143-153. PMID: 24751536

5. Pankiv S, Clausen TH, Lamark T, et al. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem. 2007;282(33):24131-24145. PMID: 17580304

6. Rogov V, Dötsch V, Johansen T, Kirkin V. Interactions between autophagy receptors and ubiquitin-like proteins form the molecular basis for selective autophagy. Mol Cell. 2014;53(2):167-178. PMID: 24462201

7. Settembre C, Di Malta C, Polito VA, et al. TFEB links autophagy to lysosomal biogenesis. Science. 2011;332(6036):1429-1433. PMID: 21617040

8. Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol. 2011;13(2):132-141. PMID: 21258367

9. Kabeya Y, Mizushima N, Ueno T, et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 2000;19(21):5720-5728. PMID: 11060023

10. Sun N, Yun J, Liu J, et al. Measuring in vivo mitophagy. Mol Cell. 2015;60(4):685-696. PMID: 26549682

11. Bjørkøy G, Lamark T, Brech A, et al. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J Cell Biol. 2005;171(4):603-614. PMID: 16286508

12. Galluzzi L, Baehrecke EH, Ballabio A, et al. Molecular definitions of autophagy and related processes. EMBO J. 2017;36(13):1811-1836. PMID: 28596378

13. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274-293. PMID: 22500797

---

For Research Use Only. This content describes experimental research reagents and signaling pathway mechanisms for in vitro laboratory investigation. Not intended for use in humans or animals.